Search research articles
Contact Us
Filters
Showing results (291-300 of 438) with videos related to
Page
of 44
Sort By:
The New England Journal of Medicine
|
October 11, 2016
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
Martin Reck, Jyoti D Patel, Jhanelle E Gray, et al.
Nature Communications
|
November 11, 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, et al.
Scientific Reports
|
March 30, 2026
Low E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma
Fiete Gehrisch, Kiara A Schmid, Martina Kluth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2006
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak, Dongsheng Tu, Lesley Seymour, et al.
Cancer Medicine
|
January 28, 2023
Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients
Julia Walter, Diego Kauffmann-Guerrero, Thomas Muley, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 14, 2024
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial
Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.
Clinical Lung Cancer
|
January 27, 2018
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
Suresh S Ramalingam, Maurice Pérol, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer
Martin Reck, Thomas Wehler, Francisco Orlandi, et al.
Page
of 44
Search research articles
Search
Showing results (291-300 of 438) with videos related to
Sort By:
Page
of 44
The New England Journal of Medicine
|
October 11, 2016
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
Martin Reck, Jyoti D Patel, Jhanelle E Gray, et al.
Nature Communications
|
November 11, 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, et al.
Scientific Reports
|
March 30, 2026
Low E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma
Fiete Gehrisch, Kiara A Schmid, Martina Kluth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2006
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak, Dongsheng Tu, Lesley Seymour, et al.
Cancer Medicine
|
January 28, 2023
Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients
Julia Walter, Diego Kauffmann-Guerrero, Thomas Muley, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 14, 2024
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial
Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.
Clinical Lung Cancer
|
January 27, 2018
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
Suresh S Ramalingam, Maurice Pérol, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer
Martin Reck, Thomas Wehler, Francisco Orlandi, et al.
Page
of 44